DCGI issues notice to Serum Institute over Oxford's Covid trial suspension

The DGCI sought an immediate reply saying else "it shall be construed that you have no explanation to offer and action deemed fit will be taken against you"

The central drug regulator has issued a show-cause notice to Serum Institute of India (SII) for not informing it about pharma giant AstraZeneca pausing the clinical trials of the Oxford vaccine candidate for Covid-19 in other countries and also for not submitting casualty analysis of the "reported serious adverse events".

The show-cause notice was issued following reports that human trials of the most promising Covid-19 vaccine candidate, being developed by the University of Oxford, have been put on hold after a UK participant had an adverse reaction to it.

The Drugs Controller General of India, Dr V G Somani, in